Market Overview

Siga Continues Rally After FDA Approves Smallpox Drug

Siga Continues Rally After FDA Approves Smallpox Drug

The U.S. Food and Drug Administration approved the first treatment of smallpox on Friday.

What Happened

Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind.

Siga stock jumped 17.6 percent Friday on the news and was trading up another 4.29 percent at the time of publication Monday morning. 

Why It’s Important

The smallpox drug's importance is twofold. On the consumer side, the approval of this treatment occurs at an integral time.

Smallpox is considered one of the deadliest diseases in human history. While it was eradicated in 1980, research and findings in the last few years suggest the disease could return. The pathogen could be used maliciously, according to the FDA. 

"Today's approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon,”  FDA Commissioner, Dr. Scott Gottlieb said in a statement. 

What's Next

As smallpox is not a direct and current threat to the population,Siga shares may not remain on a steady incline — but an increased bioterrorism threat could draw more attention to the stock. 

Related Links:

A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Lakeland Industries Grabs Investor Interest With New Ebola Cases Reported


Related Articles (SIGA)

View Comments and Join the Discussion!

Posted-In: smallpox TPOXXBiotech News FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at